Abstract
AbstractAvailable genetically defined cancer models are limited in genotypic and phenotypic complexity and underrepresent the heterogeneity of human cancer. Here, we describe a combinatorial genetic strategy applied to an organoid transformation assay to rapidly generate diverse, clinically relevant bladder and prostate cancer models. Importantly, the clonal architecture of the resultant tumors can be resolved using single-cell or spatially resolved next-generation sequencing to uncover polygenic drivers of cancer phenotypes.
Funder
U.S. Department of Health & Human Services | NIH | NIH Office of the Director
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs
Bladder Cancer Advocacy Network
U.S. Department of Health & Human Services | NIH | National Cancer Institute
University of Washington Don L. Rich Urethral Cancer Research Fund Seattle Translational Tumor Research Program in Bladder Cancer
Prostate Cancer Foundation
Seattle Translational Tumor Research Program in Bladder Cancer
Publisher
Springer Science and Business Media LLC
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献